Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up
Nema prikaza
Autori
Markićević, MilanKanjer, Ksenija
Mandušić, Vesna
Buta, Marko
Nešković-Konstantinović, Zora
Nikolić-Vukosavljević, Dragica
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker fo...r high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
Ključne reči:
cathepsin D / cutoff value / disease-free interval / early breast carcinoma / early follow-upIzvor:
Biomarkers in Medicine, 2013, 7, 5, 747-758Finansiranje / projekti:
- Molekularni biomarkeri karcinoma dojke i promena njihovog značaja u zavisnosti od perioda praćenja toka bolesti (RS-MESTD-Basic Research (BR or ON)-175068)
- Molekularne determinante za dizajn tumor markera (RS-MESTD-Basic Research (BR or ON)-173049)
DOI: 10.2217/bmm.13.62
ISSN: 1752-0363; 1752-0371
PubMed: 24044567
WoS: 000324474800015
Scopus: 2-s2.0-84884547676
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Markićević, Milan AU - Kanjer, Ksenija AU - Mandušić, Vesna AU - Buta, Marko AU - Nešković-Konstantinović, Zora AU - Nikolić-Vukosavljević, Dragica PY - 2013 UR - https://vinar.vin.bg.ac.rs/handle/123456789/5683 AB - Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up. T2 - Biomarkers in Medicine T1 - Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up VL - 7 IS - 5 SP - 747 EP - 758 DO - 10.2217/bmm.13.62 ER -
@article{ author = "Markićević, Milan and Kanjer, Ksenija and Mandušić, Vesna and Buta, Marko and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica", year = "2013", abstract = "Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.", journal = "Biomarkers in Medicine", title = "Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up", volume = "7", number = "5", pages = "747-758", doi = "10.2217/bmm.13.62" }
Markićević, M., Kanjer, K., Mandušić, V., Buta, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2013). Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up. in Biomarkers in Medicine, 7(5), 747-758. https://doi.org/10.2217/bmm.13.62
Markićević M, Kanjer K, Mandušić V, Buta M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up. in Biomarkers in Medicine. 2013;7(5):747-758. doi:10.2217/bmm.13.62 .
Markićević, Milan, Kanjer, Ksenija, Mandušić, Vesna, Buta, Marko, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up" in Biomarkers in Medicine, 7, no. 5 (2013):747-758, https://doi.org/10.2217/bmm.13.62 . .